Neutrophil-lymphocyte ratio predicts the prognosis of patients with hepatocellular carcinoma after liver transplantation

World Journal of Gastroenterology

Volumn 19, Issue 45, 2013, Pages 8398-8407

  Xiao, Guang Qin ^a   Liu, Chang ^a   Liu, Da Li ^a   Yang, Jia Yin ^a   Yan, Lu Nan ^a  

^a SICHUAN UNIVERSITY   (China)

Author keywords

Hepatitis B virus; Hepatocellular carcinoma; Inflammatory reaction; Liver transplantation; Neutrophil lymphocyte ratio

Indexed keywords

ALPHA FETOPROTEIN;

ADULT; AGE; AGED; ARTICLE; CANCER PROGNOSIS; DEATH; DISEASE FREE SURVIVAL; FEMALE; FOLLOW UP; HEPATITIS B VIRUS; HUMAN; LIVER CELL CARCINOMA; LIVER TRANSPLANTATION; LONG TERM SURVIVAL; LYMPHOCYTE; MAJOR CLINICAL STUDY; MALE; NEUTROPHIL; OVERALL SURVIVAL; PREDICTIVE VALUE; RECEIVER OPERATING CHARACTERISTIC; RISK; SENSITIVITY AND SPECIFICITY; TUMOR INVASION; TUMOR RECURRENCE; TUMOR VOLUME;

HEPATITIS B VIRUS; HEPATOCELLULAR CARCINOMA; INFLAMMATORY REACTION; LIVER TRANSPLANTATION; NEUTROPHIL-LYMPHOCYTE RATIO;

CARCINOMA, HEPATOCELLULAR; CHI-SQUARE DISTRIBUTION; CHINA; DISEASE-FREE SURVIVAL; FEMALE; HEPATITIS B; HUMANS; KAPLAN-MEIER ESTIMATE; LIVER NEOPLASMS; LIVER TRANSPLANTATION; LYMPHOCYTE COUNT; LYMPHOCYTES; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOPLASM RECURRENCE, LOCAL; NEUTROPHILS; PREDICTIVE VALUE OF TESTS; PROPORTIONAL HAZARDS MODELS; REGISTRIES; RETROSPECTIVE STUDIES; RISK FACTORS; TIME FACTORS; TREATMENT OUTCOME;

EID: 84889584210     PISSN: 10079327     EISSN: 22192840     Source Type: Journal    
DOI: 10.3748/wjg.v19.i45.8398     Document Type: Article

References (42)

1. El-Serag HB. Hepatocellular carcinoma. N Engl J Med 2011; 365: 1118-1127 [PMID: 21992124 DOI: 10.1056/NEJMra1001683]
2. Moreno P, Jaurrieta E, Figueras J, Benasco C, Rafecas A, Fabregat J, Torras J, Casanovas T, Casais L. Orthotopic liver transplantation: treatment of choice in cirrhotic patients with hepatocellular carcinoma? Transplant Proc 1995; 27: 2296-2298 [PMID: 7652813]
3. Mazzaferro V, Regalia E, Doci R, Andreola S, Pulvirenti A, Bozzetti F, Montalto F, Ammatuna M, Morabito A, Gennari L. Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N Engl J Med 1996; 334: 693-699 [PMID: 8594428 DOI: 10.1056/ nejm199603143341104]
4. Llovet JM, Bruix J, Fuster J, Castells A, Garcia-Valdecasas JC, Grande L, Franca A, Brú C, Navasa M, Ayuso MC, Solé M, Real MI, Vilana R, Rimola A, Visa J, Rodés J. Liver transplantation for small hepatocellular carcinoma: the tumor-nodemetastasis classification does not have prognostic power. Hepatology 1998; 27: 1572-1577 [PMID: 9620329 DOI: 10.1002/ hep.510270616]
5. Figueras J, Jaurrieta E, Valls C, Benasco C, Rafecas A, Xiol X, Fabregat J, Casanovas T, Torras J, Baliellas C, Ibañez L, Moreno P, Casais L. Survival after liver transplantation in cirrhotic patients with and without hepatocellular carcinoma: a comparative study. Hepatology 1997; 25: 1485-1489 [PMID: 9185772 DOI: 10.1002/hep.510250629]
6. Hemming AW, Cattral MS, Reed AI, Van Der Werf WJ, Greig PD, Howard RJ. Liver transplantation for hepatocellular carcinoma. Ann Surg 2001; 233: 652-659 [PMID: 11323504 DOI: 10.1097/00000658-200105000-00009]
7. Yoo HY, Patt CH, Geschwind JF, Thuluvath PJ. The outcome of liver transplantation in patients with hepatocellular carcinoma in the United States between 1988 and 2001: 5-year survival has improved significantly with time. J Clin Oncol 2003; 21: 4329-4335 [PMID: 14581446 DOI: 10.1200/ jco.2003.11.137]
8. Yao FY, Ferrell L, Bass NM, Watson JJ, Bacchetti P, Venook A, Ascher NL, Roberts JP. Liver transplantation for hepatocellular carcinoma: expansion of the tumor size limits does not adversely impact survival. Hepatology 2001; 33: 1394-1403 [PMID: 11391528 DOI: 10.1053/jhep.2001.24563]
9. Duffy JP, Vardanian A, Benjamin E, Watson M, Farmer DG, Ghobrial RM, Lipshutz G, Yersiz H, Lu DS, Lassman C, Tong MJ, Hiatt JR, Busuttil RW. Liver transplantation criteria for hepatocellular carcinoma should be expanded: a 22-year experience with 467 patients at UCLA. Ann Surg 2007; 246: 502-509, discussion 509-511 [PMID: 17717454 DOI: 10.1097/ SLA.0b013e318148c704]
10. Silva M, Moya A, Berenguer M, Sanjuan F, López-Andujar R, Pareja E, Torres-Quevedo R, Aguilera V, Montalva E, De Juan M, Mattos A, Prieto M, Mir J. Expanded criteria for liver transplantation in patients with cirrhosis and hepatocellular carcinoma. Liver Transpl 2008; 14: 1449-1460 [PMID: 18825681 DOI: 10.1002/lt.21576]
11. Yao FY. Liver transplantation for hepatocellular carcinoma: beyond the Milan criteria. Am J Transplant 2008; 8: 1982-1989 [PMID: 18727702 DOI: 10.1111/j.1600-6143.2008.02351.x]
12. Ito T, Takada Y, Ueda M, Haga H, Maetani Y, Oike F, Ogawa K, Sakamoto S, Ogura Y, Egawa H, Tanaka K, Uemoto S. Expansion of selection criteria for patients with hepatocellular carcinoma in living donor liver transplantation. Liver Transpl 2007; 13: 1637-1644 [PMID: 18044766 DOI: 10.1002/ lt.21281]
13. Jonas S, Bechstein WO, Steinmüller T, Herrmann M, Radke C, Berg T, Settmacher U, Neuhaus P. Vascular invasion and histopathologic grading determine outcome after liver transplantation for hepatocellular carcinoma in cirrhosis. Hepatology 2001; 33: 1080-1086 [PMID: 11343235 DOI: 10.1053/ jhep.2001.23561]
14. Schwartz ME, D'Amico F, Vitale A, Emre S, Cillo U. Liver transplantation for hepatocellular carcinoma: Are the Milan criteria still valid? Eur J Surg Oncol 2008; 34: 256-262 [PMID: 18029133 DOI: 10.1016/j.ejso.2007.07.208]
15. Balkwill F, Mantovani A. Inflammation and cancer: back to Virchow? Lancet 2001; 357: 539-545 [PMID: 11229684 DOI: 10.1016/S0140-6736(00)04046-0]
16. Coussens LM, Werb Z. Inflammation and cancer. Nature 2002; 420: 860-867 [PMID: 12490959 DOI: 10.1038/nature01322]
17. Mantovani A, Allavena P, Sica A, Balkwill F. Cancer-related inflammation. Nature 2008; 454: 436-444 [PMID: 18650914 DOI: 10.1038/nature07205]
18. Hashimoto K, Ikeda Y, Korenaga D, Tanoue K, Hamatake M, Kawasaki K, Yamaoka T, Iwatani Y, Akazawa K, Takenaka K. The impact of preoperative serum C-reactive protein on the prognosis of patients with hepatocellular carcinoma. Cancer 2005; 103: 1856-1864 [PMID: 15779015 DOI: 10.1002/ cncr.20976]
19. Hefler LA, Concin N, Hofstetter G, Marth C, Mustea A, Sehouli J, Zeillinger R, Leipold H, Lass H, Grimm C, Tempfer CB, Reinthaller A. Serum C-reactive protein as independent prognostic variable in patients with ovarian cancer. Clin Cancer Res 2008; 14: 710-714 [PMID: 18245530 DOI: 10.1158/1078-0432.CCR-07-1044]
20. Nakahara Y, Mochiduki Y, Miyamoto Y, Nakahara Y, Katsura Y. Prognostic significance of the lymphocyte-toneutrophil ratio in percutaneous fine-needle aspiration biopsy specimens of advanced nonsmall cell lung carcinoma. Cancer 2005; 104: 1271-1280 [PMID: 16047345 DOI: 10.1002/ cncr.21290]
21. Shimada H, Takiguchi N, Kainuma O, Soda H, Ikeda A, Cho A, Miyazaki A, Gunji H, Yamamoto H, Nagata M. High preoperative neutrophil-lymphocyte ratio predicts poor survival in patients with gastric cancer. Gastric Cancer 2010; 13: 170-176 [PMID: 20820986 DOI: 10.1007/s10120-010-0554-3]
22. Chua W, Charles KA, Baracos VE, Clarke SJ. Neutrophil/ lymphocyte ratio predicts chemotherapy outcomes in patients with advanced colorectal cancer. Br J Cancer 2011; 104: 1288-1295 [PMID: 21448173 DOI: 10.1038/bjc.2011.100]
23. Halazun KJ, Aldoori A, Malik HZ, Al-Mukhtar A, Prasad KR, Toogood GJ, Lodge JP. Elevated preoperative neutrophil to lymphocyte ratio predicts survival following hepatic resection for colorectal liver metastases. Eur J Surg Oncol 2008; 34: 55-60 [PMID: 17448623 DOI: 10.1016/j.ejso.2007.02.014]
24. Wang GY, Yang Y, Li H, Zhang J, Jiang N, Li MR, Zhu HB, Zhang Q, Chen GH. A scoring model based on neutrophil to lymphocyte ratio predicts recurrence of HBV-associated hepatocellular carcinoma after liver transplantation. PLoS One 2011; 6: e25295 [PMID: 21966488 DOI: 10.1371/journal. pone.0025295]
25. Halazun KJ, Hardy MA, Rana AA, Woodland DC, Luyten EJ, Mahadev S, Witkowski P, Siegel AB, Brown RS, Emond JC. Negative impact of neutrophil-lymphocyte ratio on outcome after liver transplantation for hepatocellular carcinoma. Ann Surg 2009; 250: 141-151 [PMID: 19561458 DOI: 10.1097/SLA.0b013e3181a77e59]
26. Bertuzzo VR, Cescon M, Ravaioli M, Grazi GL, Ercolani G, Del Gaudio M, Cucchetti A, D'Errico-Grigioni A, Golfieri R, Pinna AD. Analysis of factors affecting recurrence of hepatocellular carcinoma after liver transplantation with a special focus on inflammation markers. Transplantation 2011; 91: 1279-1285 [PMID: 21617590 DOI: 10.1097/ TP.0b013e3182187cf0]
27. Motomura T, Shirabe K, Mano Y, Muto J, Toshima T, Umemoto Y, Fukuhara T, Uchiyama H, Ikegami T, Yoshizumi T, Soejima Y, Maehara Y. Neutrophil-lymphocyte ratio reflects hepatocellular carcinoma recurrence after liver transplantation via inflammatory microenvironment. J Hepatol 2013; 58: 58-64 [PMID: 22925812 DOI: 10.1016/ j.jhep.2012.08.017]
28. Yoshizumi T, Ikegami T, Yoshiya S, Motomura T, Mano Y, Muto J, Ikeda T, Soejima Y, Shirabe K, Maehara Y. Impact of tumor size, number of tumors and neutrophil-to-lymphocyte ratio in liver transplantation for recurrent hepatocellular carcinoma. Hepatol Res 2013; 43: 709-716 [PMID: 23190306 DOI: 10.1111/hepr.12016]
29. Todo S, Furukawa H. Living donor liver transplantation for adult patients with hepatocellular carcinoma: experience in Japan. Ann Surg 2004; 240: 451-459, discussion 459-461 [PMID: 15319716]
30. Jiang L, Yan LN. Current therapeutic strategies for recurrent hepatitis B virus infection after liver transplantation. World J Gastroenterol 2010; 16: 2468-2475 [PMID: 20503446 DOI: 10.3748/wjg.v16.i20.2468]
31. Li J, Yan LN, Yang J, Chen ZY, Li B, Zeng Y, Wen TF, Zhao JC, Wang WT, Yang JY, Xu MQ, Ma YK. Indicators of prognosis after liver transplantation in Chinese hepatocellular carcinoma patients. World J Gastroenterol 2009; 15: 4170-4176 [PMID: 19725152 DOI: 10.3748/wjg.15.4170]
32. Nakashima T, Okuda K, Kojiro M, Jimi A, Yamaguchi R, Sakamoto K, Ikari T. Pathology of hepatocellular carcinoma in Japan. 232 Consecutive cases autopsied in ten years. Cancer 1983; 51: 863-877 [PMID: 6295617 DOI: 10.1002/1097-0142 (19830301)51:5<863::AID-CNCR2820510520>3.0.CO;2-D]
33. Pawlik TM, Delman KA, Vauthey JN, Nagorney DM, Ng IO, Ikai I, Yamaoka Y, Belghiti J, Lauwers GY, Poon RT, Abdalla EK. Tumor size predicts vascular invasion and histologic grade: Implications for selection of surgical treatment for hepatocellular carcinoma. Liver Transpl 2005; 11: 1086-1092 [PMID: 16123959 DOI: 10.1002/lt.20472]
34. Brodsky SV, Mendelev N, Melamed M, Ramaswamy G. Vascular density and VEGF expression in hepatic lesions. J Gastrointestin Liver Dis 2007; 16: 373-377 [PMID: 18193117]
35. Holash J, Wiegand SJ, Yancopoulos GD. New model of tumor angiogenesis: dynamic balance between vessel regression and growth mediated by angiopoietins and VEGF. Oncogene 1999; 18: 5356-5362 [PMID: 10498889]
36. Ferrara N. Pathways mediating VEGF-independent tumor angiogenesis. Cytokine Growth Factor Rev 2010; 21: 21-26 [PMID: 20005148 DOI: 10.1016/j.cytogfr.2009.11.003]
37. Saharinen P, Eklund L, Pulkki K, Bono P, Alitalo K. VEGF and angiopoietin signaling in tumor angiogenesis and metastasis. Trends Mol Med 2011; 17: 347-362 [PMID: 21481637 DOI: 10.1016/j.molmed.2011.01.015]
38. Finn RS, Zhu AX. Targeting angiogenesis in hepatocellular carcinoma: focus on VEGF and bevacizumab. Expert Rev Anticancer Ther 2009; 9: 503-509 [PMID: 19374603 DOI: 10.1586/ era.09.6]
39. Kaseb AO, Hanbali A, Cotant M, Hassan MM, Wollner I, Philip PA. Vascular endothelial growth factor in the management of hepatocellular carcinoma: a review of literature. Cancer 2009; 115: 4895-4906 [PMID: 19637355 DOI: 10.1002/ cncr.24537]
40. Chew V, Chen J, Lee D, Loh E, Lee J, Lim KH, Weber A, Slankamenac K, Poon RT, Yang H, Ooi LL, Toh HC, Heikenwalder M, Ng IO, Nardin A, Abastado JP. Chemokinedriven lymphocyte infiltration: an early intratumoural event determining long-term survival in resectable hepatocellular carcinoma. Gut 2012; 61: 427-438 [PMID: 21930732 DOI: 10.1136/gutjnl-2011-300509]
41. Vibert E, Azoulay D, Hoti E, Iacopinelli S, Samuel D, Salloum C, Lemoine A, Bismuth H, Castaing D, Adam R. Progression of alphafetoprotein before liver transplantation for hepatocellular carcinoma in cirrhotic patients: a critical factor. Am J Transplant 2010; 10: 129-137 [PMID: 20070666 DOI: 10.1111/j.1600-6143.2009.02750.x]
42. Löhe F, Angele MK, Rentsch M, Graeb C, Gerbes A, Löhrs U, Beuers U, Jauch KW. Multifocal manifestation does not affect vascular invasion of hepatocellular carcinoma: implications for patient selection in liver transplantation. Clin Transplant 2007; 21: 696-701 [PMID: 17988261]